Source: Eur Respir J, 50 (1) 1700598; 10.1183/13993003.00598-2017
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Lorenzo Guglielmetti, Francis Varaine, Helena Huerga, Maryline Bonnet, Michael L. Rich, Carole D. Mitnick. Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance. Eur Respir J, 50 (1) 1700598; 10.1183/13993003.00598-2017

Member's Comments

No comment yet.

Related content which might interest you: Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients Source: Eur Respir J 2013; 42: 1614-1621 Year: 2013 Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance Source: Eur Respir J, 49 (6) 1700223; 10.1183/13993003.00223-2017 Year: 2017 Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013 Increasing incidence of fluoroquinolone resistant tuberculosis in Bombay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen Source: Eur Respir J, 52 (6) 1801528; 10.1183/13993003.01528-2018 Year: 2018 The prevalence of pyrazinamide resistance in multidrug resistant tuberculosis cases in the Netherlands Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis Year: 2012 Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Source: Eur Respir J 2009; 34: 1492-1494 Year: 2009 Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Linezolid in multidrug-resistant tuberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 485s Year: 2004 Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015 Source: Eur Respir J , 49 (4)  1602309; DOI: 10.1183/13993003.02309-2016 Year: 2017 Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012